Cartalax for Joint & Cartilage Tissue Support — Bioregulators
Khavinson bioregulator peptide for cartilage regeneration and musculoskeletal health optimization.
Overview
Cartalax is a Khavinson bioregulator specifically targeting cartilage and musculoskeletal tissues. It consists of short-chain peptides that interact with DNA in chondrocytes and connective tissue cells to restore youthful gene expression patterns. Cartalax supports joint health, cartilage regeneration, and musculoskeletal tissue repair through epigenetic modulation of tissue-specific genes. It's particularly valuable for age-related joint degeneration, osteoarthritis support, and athletic joint health maintenance.
Indications
- Osteoarthritis and joint degeneration
- Cartilage tissue repair and regeneration
- Musculoskeletal health in aging
- Athletic joint stress and overuse
- Post-injury cartilage recovery
- Chronic joint pain and stiffness
- Connective tissue health optimization
Mechanism of Action
Age-related cartilage loss, osteoarthritis, or mechanical joint stress leading to tissue breakdown
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Cartalax | 20 mg | Once daily | Maintenance dosing for joint health |
| Cartalax | 20 mg | Twice daily for first 2-4 weeks, then once daily | For active osteoarthritis or post-injury recovery |
Safety & Contraindications
- Emerging evidence - primarily Russian clinical experience
- No reported toxic or adverse effects in clinical studies
- Generally well-tolerated for long-term use
- Not a replacement for orthopedic interventions in severe cases
- Safe to combine with standard joint supplements (glucosamine, chondroitin)
- Consult physician before use with severe arthritis or joint conditions